These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 37424799)

  • 61. Shorter survival-times following adjuvant endocrine therapy in oestrogen- and progesterone-receptor positive breast cancer overexpressing HER2 and/or with an increased expression of vascular endothelial growth factor.
    Linderholm B; Bergqvist J; Hellborg H; Johansson U; Linderholm M; von Schoultz E; Elmberger G; Skoog L; Bergh J
    Med Oncol; 2009 Dec; 26(4):480-90. PubMed ID: 19130322
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Characterization of male breast cancer: results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program.
    Cardoso F; Bartlett JMS; Slaets L; van Deurzen CHM; van Leeuwen-Stok E; Porter P; Linderholm B; Hedenfalk I; Schröder C; Martens J; Bayani J; van Asperen C; Murray M; Hudis C; Middleton L; Vermeij J; Punie K; Fraser J; Nowaczyk M; Rubio IT; Aebi S; Kelly C; Ruddy KJ; Winer E; Nilsson C; Lago LD; Korde L; Benstead K; Bogler O; Goulioti T; Peric A; Litière S; Aalders KC; Poncet C; Tryfonidis K; Giordano SH
    Ann Oncol; 2018 Feb; 29(2):405-417. PubMed ID: 29092024
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Response to neoadjuvant chemotherapy based on pathologic complete response in very young patients with ER-positive breast cancer: a large, multicenter, observational study.
    Woo J; Oh SJ; Song JY; Chae BJ; Choi JE; Lee J; Park HK; ; Lim W
    BMC Cancer; 2021 May; 21(1):647. PubMed ID: 34059020
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Molecular Subtype May Be More Associated With Prognosis and Chemotherapy Benefit Than Tumor Size in T1N0 Breast Cancer Patients: An Analysis of 2,168 Patients for Possible De-Escalation Treatment.
    Zhu S; Li Y; Chen W; Fei X; Shen K; Chen X
    Front Oncol; 2021; 11():636266. PubMed ID: 33680973
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Prognostic Impact of Progesterone Receptor Status in Chinese Estrogen Receptor Positive Invasive Breast Cancer Patients.
    Yao N; Song Z; Wang X; Yang S; Song H
    J Breast Cancer; 2017 Jun; 20(2):160-169. PubMed ID: 28690652
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Influence of progesterone receptor on metastasis and prognosis in breast cancer patients with negative HER-2.
    Xiao Y; Li J; Wu Z; Zhang X; Ming J
    Gland Surg; 2022 Jan; 11(1):77-90. PubMed ID: 35242671
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Prognostic value of breast cancer subtypes, Ki-67 proliferation index, age, and pathologic tumor characteristics on breast cancer survival in Caucasian women.
    Ferguson NL; Bell J; Heidel R; Lee S; Vanmeter S; Duncan L; Munsey B; Panella T; Orucevic A
    Breast J; 2013; 19(1):22-30. PubMed ID: 23240985
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Assessment of 25-Year Survival of Women With Estrogen Receptor-Positive/ERBB2-Negative Breast Cancer Treated With and Without Tamoxifen Therapy: A Secondary Analysis of Data From the Stockholm Tamoxifen Randomized Clinical Trial.
    Dar H; Johansson A; Nordenskjöld A; Iftimi A; Yau C; Perez-Tenorio G; Benz C; Nordenskjöld B; Stål O; Esserman LJ; Fornander T; Lindström LS
    JAMA Netw Open; 2021 Jun; 4(6):e2114904. PubMed ID: 34190995
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Breast cancer-specific survival by clinical subtype after 7 years follow-up of young and elderly women in a nationwide cohort.
    Johansson ALV; Trewin CB; Hjerkind KV; Ellingjord-Dale M; Johannesen TB; Ursin G
    Int J Cancer; 2019 Mar; 144(6):1251-1261. PubMed ID: 30367449
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Computational Inferences of the Functions of Alternative/Noncanonical Splice Isoforms Specific to HER2+/ER-/PR- Breast Cancers, a Chromosome 17 C-HPP Study.
    Menon R; Panwar B; Eksi R; Kleer C; Guan Y; Omenn GS
    J Proteome Res; 2015 Sep; 14(9):3519-29. PubMed ID: 26147891
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Biomarker Discordances and Alterations Observed in Breast Cancer Treated with Neoadjuvant Chemotherapy: Causes, Frequencies, and Clinical Significances.
    Yilmaz C; Cavdar DK
    Curr Oncol; 2022 Dec; 29(12):9695-9710. PubMed ID: 36547175
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Mammographic Density Decline, Tamoxifen Response, and Prognosis by Molecular Characteristics of Estrogen Receptor-Positive Breast Cancer.
    Abubakar M; Mullooly M; Nyante S; Pfeiffer RM; Aiello Bowles EJ; Cora R; Bodelon C; Butler E; Butcher D; Sternberg L; Troester MA; Weinmann S; Sherman M; Glass AG; Berrington de Gonzalez A; Gierach GL
    JNCI Cancer Spectr; 2022 May; 6(3):. PubMed ID: 35583138
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Long-term treatment efficacy in primary inflammatory breast cancer by hormonal receptor- and HER2-defined subtypes.
    Masuda H; Brewer TM; Liu DD; Iwamoto T; Shen Y; Hsu L; Willey JS; Gonzalez-Angulo AM; Chavez-MacGregor M; Fouad TM; Woodward WA; Reuben JM; Valero V; Alvarez RH; Hortobagyi GN; Ueno NT
    Ann Oncol; 2014 Feb; 25(2):384-91. PubMed ID: 24351399
    [TBL] [Abstract][Full Text] [Related]  

  • 74. A Two-Step Feature Selection Radiomic Approach to Predict Molecular Outcomes in Breast Cancer.
    Brancato V; Brancati N; Esposito G; La Rosa M; Cavaliere C; Allarà C; Romeo V; De Pietro G; Salvatore M; Aiello M; Sangiovanni M
    Sensors (Basel); 2023 Jan; 23(3):. PubMed ID: 36772592
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Disparities in the risk of the ER/PR/HER2 breast cancer subtypes among Asian Americans in California.
    Parise C; Caggiano V
    Cancer Epidemiol; 2014 Oct; 38(5):556-62. PubMed ID: 25172158
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Long-term hazard of recurrence in HER2+ breast cancer patients untreated with anti-HER2 therapy.
    Strasser-Weippl K; Horick N; Smith IE; O'Shaughnessy J; Ejlertsen B; Boyle F; Buzdar AU; Fumoleau P; Gradishar W; Martin M; Moy B; Piccart-Gebhart M; Pritchard KI; Lindquist D; Rappold E; Finkelstein DM; Goss PE
    Breast Cancer Res; 2015 Apr; 17(1):56. PubMed ID: 25888246
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Lack of either estrogen or progesterone receptor expression is associated with poor survival outcome among luminal A breast cancer subtype.
    Park S; Park BW; Kim TH; Jeon CW; Kang HS; Choi JE; Hwang KT; Kim IC
    Ann Surg Oncol; 2013 May; 20(5):1505-13. PubMed ID: 23192228
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Long-Term Outcomes of Immunohistochemically Defined Subtypes of Breast Cancer Less Than or Equal to 2 cm After Breast-Conserving Surgery.
    Pata G; Guaineri A; Bianchi A; Amoroso V; Pasinetti N; Pasini M
    J Surg Res; 2019 Apr; 236():288-299. PubMed ID: 30694768
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Prevalence of Breast Cancer Subtypes Among Different Ethnicities and Bangladeshi Women: Demographic, Clinicopathological, and Integrated Cancer Informatics Analysis.
    Islam D; Islam MS; Dorin SI; Jesmin
    Cancer Inform; 2023; 22():11769351221148584. PubMed ID: 36684416
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Characteristics and survival in bone metastatic breast cancer patients with different hormone receptor status: A population-based cohort study.
    Jiang X; Chen G; Sun L; Liu C; Zhang Y; Liu M; Liu C
    Front Oncol; 2022; 12():977226. PubMed ID: 36091103
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.